Cytori Therapeutics, Inc. (CYTX) Stock: Is This Biotechnology Stock Worth Your Attention? – iWatch Markets

Cytori Therapeutics, Inc. (CYTX) is falling in the market today. The stock, focused in the biotechnology industry, is currently priced at $0.24 after heading down -5.66% so far today. In terms of biotech stocks, there are quite a few factors that have the potential to generate movement in the market. News is one of the most common reasons for movement. Here are the recent headlines relating to CYTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nonetheless, when making an investing decision, prospective investors should focus on far more than news, especially in the generally speculative biotechnology industry. Here’s what’s happing when it comes to Cytori Therapeutics, Inc..

What We’ve Seen From CYTX

While a decline in a single session, like the move that we’re seeing from Cytori Therapeutics, Inc. may make some investors tremble, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is generally smart to look into trends experienced by the stock beyond a single trading day. As it relates to CYTX, here are the movements that investors have seen:

  • Past 5 Trading Sessions – Over the last 7 days, CYTX has produced a change in price amounting to -9.43%.
  • Monthly – The return from Cytori Therapeutics, Inc. in the last month has been -23.54%.
  • Past Quarter – Throughout the past quarter, the company has generated a ROI that comes to -9.60%
  • Past Six Months – Throughout the past six months, we’ve seen a change that equates to -31.03% from the company.
  • Year To Date – Since the the last trading session of last year CYTX has produced a return on investment of -17.24%.
  • Full Year – Lastly, in the past full year, we have seen performance in the amount of -91.52% out of CYTX. Over this period of time, the stock has traded at a high price of -92.00% and a low price of 11.63%.

Key Ratios

Looking at various key ratios having to do with a company generally gives prospective traders a look of how risky and/or potentially profitable a an investment option may be. Here are some of the important ratios to look at when looking at CYTX.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the amount of short interest. As the short ratio heads up, it means that more investors have a belief that the price of the stock is headed for declines. Throughout the sector, biotech stocks can come with a higher short ratio. However, we also see a lot of short squeezes in the industry. Nonetheless, as it relates to Cytori Therapeutics, Inc., it’s short ratio is 0.03.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Basically, they measure the company’s abilities to cover its debts when they come due based on current assets or quick assets. In the biotechnology sector, many companies are heavily reliant on the continuation of investor support, these ratios can seem bad. However, several good picks in the biotechnology industry come with strong current and quick ratios. In terms of CYTX, the quick and current ratios come to 0.40 and 0.50 respectively.  

Book To Share Value – The book to share value compares the the share price to the book value of assets that are owned by the company. In this particular case, that ratio works out to 0.38.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to think about. As it relates to CYTX, the cash to share value ratio comes to 0.24.

How Analysts Feel About Cytori Therapeutics, Inc.

Although it’s not a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their opinions when validating your own before making an investment decision in the biotechnology sector. Here are the recent moves that we’ve seen from analysts when it comes to CYTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-11-17ReiteratedMaxim GroupBuy$10 → $5
Jul-25-17DowngradeB. Riley & Co.Buy → Neutral
Aug-10-15ReiteratedROTH CapitalBuy$6 → $4
Jan-16-15ReiteratedROTH CapitalBuy$3.50 → $6

Is Big Money Interested In Cytori Therapeutics, Inc.

One thing that I have learned so far in my short time on Earth is that smart investors tend to follow big money. In other words, investors that are trying to keep their investments relatively safe will pay close attention to investments made by institutional investors as well as insiders of the company. With that said, is big money flowing when it comes to CYTX? Here’s the scoop:

Institutions own 4.50% of the company. Institutional interest has moved by 9.08% over the past three months. When it comes to insiders, those who are close to the company currently own 1.96% percent of CYTX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 21.89M shares of Cytori Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CYTX has a float of 21.59M.

I also find it important to pay attention to the short percent. After all, when a high portion of the float is sold short, the overall feeling in the market is that the stock is headed for a deep dive. In regard to CYTX, the percentage of the float that is shorted currently sits at 0.10%. Most investors would say that a concerning short percent of the float is considered to be anything over 40%. Nonetheless, I’ve seen that a short percent of the float over 26% is usually a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from CYTX in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – As it stands, Wall Street analysts are expecting that the company will create EPS that comes to -0.48, with -0.20 to be reported in the report for the current quarter. Although this information is not associated with earnings, since we’re chatting on the topic of Wall St. analysts, Cytori Therapeutics, Inc. is presently rated a 2.00 when rated on a scale from 1 to 5 on which 1 is the worst average Wall St. analyst grade and 5 is the best.
  • 5-Year Sales – Over the past half decade, Cytori Therapeutics, Inc. has announced a movement in revenue that works out to -11.40%. Earnings per share through the period have experienced movement in the amount of 50.40%.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is often explained in today’s society, the company has seen a earnings change by 92.00%. CYTX has also seen movement in terms of revenue that amounts to 40.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I’m highly dependent on human beings. After all, humans built me! Even though my developer enabled me to learn by myself, it is a lot simpler to learn when I receive human feedback. Below this content, you’ll find a comment section. If you’d like for me to look at other data, change the way I communicate, look at information from an alternative angle, or you’re interested in telling me anything else, I’d love to learn. Please consider leaving a comment below. I’ll process that comment and it will help me become a better artificial intelligence to serve you!

read original article at